STAT

‘We need an army’: Hiring of coronavirus trackers seen as key to curbing disease spread

“We need an army of 300,000 people” to find the contacts of people infected with the #coronavirus, said former CDC director Tom Frieden.
Riders on the New York City subway last week wear personal protective equipment.

K.J. Seung is surprised to be hiring and training new workers in Boston.

His public health nonprofit, Partners in Health, specializes in helping the poorest people in developing nations — tracking down contacts of Ebola patients in Liberia and Sierra Leone; running child health and HIV clinics in Haiti; and operating tuberculosis control programs in Peru. But now it is advertising for 500 people to help do what’s known as contact tracing to try to control Covid-19 in Massachusetts.

It’s the first step in the next stage of fighting the pandemic. Boston-based Partners in Health has trained 12,000 community health workers in countries including Malawi, Mexico, and Rwanda and now it will help train a battalion of workers in Massachusetts to interview everyone diagnosed with Covid-19 and find other people who may have been infected by them. This old-fashioned, shoe-leather public health approach contained the SARS outbreak in 2003 and 2004, and public health experts agree it will

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About MDMA For PTSD, A CRISPR Treatment For Blindness, And More
An FDA advisory panel will deliberate on June 4 whether to recommend approval for the first MDMA-assisted therapy for post-traumatic stress disorder.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About MorphoSys Drug Risks, An AstraZeneca Admission, And More
MorphoSys is dealing with a safety issue with pelabresib, the experimental treatment for myelofibrosis and centerpiece of its proposed $3 billion acquisition by Novartis.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About An Amgen Obesity Drug, A Senate Bill On Shortages, And More
Amgen will no longer develop an early-stage obesity pill, and will instead focus on a more advanced injectable candidate to compete with Wegovy and Zepbound.

Related Books & Audiobooks